TW200618795A - Amorphous atorvastatin calcium - Google Patents

Amorphous atorvastatin calcium

Info

Publication number
TW200618795A
TW200618795A TW094134218A TW94134218A TW200618795A TW 200618795 A TW200618795 A TW 200618795A TW 094134218 A TW094134218 A TW 094134218A TW 94134218 A TW94134218 A TW 94134218A TW 200618795 A TW200618795 A TW 200618795A
Authority
TW
Taiwan
Prior art keywords
atorvastatin calcium
amorphous atorvastatin
amorphous
stability
calcium
Prior art date
Application number
TW094134218A
Other languages
English (en)
Inventor
Srinivasulu Gudipati
Srinivas Katkam
Satyanarayana Komati
Satyanarayana Jaya Kudavalli
Original Assignee
Reddys Lab Ltd Dr
Reddys Lab Inc Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr, Reddys Lab Inc Dr filed Critical Reddys Lab Ltd Dr
Publication of TW200618795A publication Critical patent/TW200618795A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW094134218A 2004-09-30 2005-09-30 Amorphous atorvastatin calcium TW200618795A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61457804P 2004-09-30 2004-09-30
IN715CH2005 2005-06-10

Publications (1)

Publication Number Publication Date
TW200618795A true TW200618795A (en) 2006-06-16

Family

ID=36143063

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094134218A TW200618795A (en) 2004-09-30 2005-09-30 Amorphous atorvastatin calcium

Country Status (7)

Country Link
US (1) US20080009540A1 (zh)
EP (1) EP1793815A4 (zh)
JP (1) JP2008514722A (zh)
KR (1) KR20070106680A (zh)
CA (1) CA2582449A1 (zh)
TW (1) TW200618795A (zh)
WO (1) WO2006039441A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
EP2075246A1 (en) * 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2009090544A2 (en) * 2008-01-16 2009-07-23 Matrix Laboratories Limited Process for producing amorphous atorvastatin calcium
WO2010066687A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Stabalized statin-comprising compositions
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
US20150251998A1 (en) * 2012-09-17 2015-09-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process to produce atorvastatin intermediates
JPWO2017042995A1 (ja) * 2015-09-07 2018-06-28 パナソニックIpマネジメント株式会社 車載用ステレオカメラ装置、およびその補正方法
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210840A (en) * 1984-01-18 1987-05-29 Johnson & Johnson Baby Prod Composition comprising synergistic combination of miconazole nitrate and zinc oxide
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6673374B2 (en) * 1998-07-31 2004-01-06 Howard Murad Pharmaceutical compositions and methods for managing skin conditions
JP2002035579A (ja) * 2000-07-24 2002-02-05 Mitsubishi Gas Chem Co Inc 水蒸気を吸収する脱酸素剤組成物
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IN190564B (zh) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
KR20040101229A (ko) * 2002-02-14 2004-12-02 랜박시 래보러터리스 리미티드 알칼리 금속 첨가에 의해 안정화된 아토르바스타틴 배합물
JP4422488B2 (ja) * 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
TW200513199A (en) * 2003-08-12 2005-04-16 Mitsubishi Gas Chemical Co Oxygen absorber composition, oxygen absorber packaging and oxygen absorption method
US7618953B2 (en) * 2004-02-26 2009-11-17 Zentiva, A.S. Amorphous forms of risedronate monosodium
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
MXPA06010665A (es) * 2004-03-19 2007-03-28 Pharmed Medicare Pvt Ltd Un proceso mejorado para producir sacarosa clorada.

Also Published As

Publication number Publication date
WO2006039441A3 (en) 2006-07-20
JP2008514722A (ja) 2008-05-08
WO2006039441A2 (en) 2006-04-13
US20080009540A1 (en) 2008-01-10
KR20070106680A (ko) 2007-11-05
EP1793815A4 (en) 2010-12-29
CA2582449A1 (en) 2006-04-13
EP1793815A2 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
TW200618795A (en) Amorphous atorvastatin calcium
PL1727795T3 (pl) Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
SI1915349T1 (sl) Postopek za pripravo čistega amorfnega rosuvastatin kalcija
AU307406S (en) Packaging
IL169186A0 (en) Pyridodiazines as plant fungicides
PL1794302T3 (pl) Sposób zwiększania masy nasienia
WO2006111389A3 (de) Transparente polyamidfolien
PL1776401T3 (pl) Polimery kationowe zawierające 2-hydroksyetyl-metakrylowy jako promotory zaklejania z wykorzystaniem ASA
TW200637832A (en) Process for preparing amorphous valsartan
MXPA03004986A (es) Proceso para preparar polimeros de emulsion con alta pureza.
MX2007004423A (es) Calcio de rosuvastatina con bajo contenido de sal.
UA91733C2 (ru) Способ получения кристаллической формы орлистата
HU0300761D0 (en) Process for the production of amorphous atorvastatin calcium
AP1585A (en) Plastic foil.
TW200510362A (en) Amorphous simvastatin calcium and methods for the preparation thereof
AU2002356423A1 (en) Process for the preparation of amorphous atorvastatin calcium
TH79580B (th) อะทอร์วาสแตตินแคลเซียมอสัณฐาน
TW200505790A (en) Surface- modified precipitated silicas
TH79580A (th) อะทอร์วาสแตตินแคลเซียมอสัณฐาน
GB0417368D0 (en) Improvements relating to packaging
TW200700474A (en) Transparente polyamidfolien
AU2003252194A1 (en) Vertical system for growing plants
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
TW200637495A (en) Novel composite for inhibiting algae growth and use thereof
TW564671U (en) An improved packing sheet for potted plants